Education
About Us
Working with TipRanks
Follow Us
Krystal Biotech (KRYS)
NASDAQ:KRYS
Total Valuation
Krystal Biotech has a market cap or net worth of $7.63B. The enterprise value is $7.14B.
Market Cap$7.63B
Enterprise Value$7.14B
Share Statistics
Krystal Biotech has 29,232,190 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding29,232,190
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Krystal Biotech’s return on equity (ROE) is 0.17 and return on invested capital (ROIC) is 13.09%.
Return on Equity (ROE)0.17
Return on Assets (ROA)0.15
Return on Invested Capital (ROIC)13.09%
Return on Capital Employed (ROCE)0.13
Revenue Per Employee1.42M
Profits Per Employee744.84K
Employee Count275
Asset Turnover0.29
Inventory Turnover0.71
Valuation Ratios
The current PE Ratio of Krystal Biotech is 34.8. Krystal Biotech’s PEG ratio is 0.27.
PE Ratio34.8
PS Ratio18.34
PB Ratio5.85
Price to Fair Value5.85
Price to FCF37.77
Price to Operating Cash Flow37.62
PEG Ratio0.27
Income Statement
In the last 12 months, Krystal Biotech had revenue of 389.13M and earned 204.83M in profits. Earnings per share was 7.08.
Revenue389.13M
Gross Profit360.36M
Operating Income161.29M
Pretax Income189.47M
Net Income204.83M
EBITDA167.85M
Earnings Per Share (EPS)7.08
Cash Flow
In the last 12 months, operating cash flow was 200.87M and capital expenditures -11.95M, giving a free cash flow of 188.91M billion.
Operating Cash Flow200.87M
Free Cash Flow188.91M
Free Cash Flow per Share6.46
Dividends & Yields
Krystal Biotech pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.72
52-Week Price Change41.22%
50-Day Moving Average269.14
200-Day Moving Average194.89
Relative Strength Index (RSI)45.98
Average Volume (3m)283.01K
Important Dates
Krystal Biotech upcoming earnings date is May 11, 2026, Before Open (Confirmed).
Last Earnings DateFeb 17, 2026
Next Earnings DateMay 11, 2026
Ex-Dividend Date―
Financial Position
Krystal Biotech as a current ratio of 9.95, with Debt / Equity ratio of 0.77%
Current Ratio9.95
Quick Ratio9.56
Debt to Market Cap0.00
Net Debt to EBITDA-2.90
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Krystal Biotech has paid -15.36M in taxes.
Income Tax-15.36M
Effective Tax Rate-0.08
Enterprise Valuation
Krystal Biotech EV to EBITDA ratio is 39.61, with an EV/FCF ratio of 35.20.
EV to Sales17.09
EV to EBITDA39.61
EV to Free Cash Flow35.20
EV to Operating Cash Flow33.10
Balance Sheet
Krystal Biotech has $827.79M in cash and marketable securities with $9.34M in debt, giving a net cash position of $818.45M billion.
Cash & Marketable Securities$827.79M
Total Debt$9.34M
Net Cash$818.45M
Net Cash Per Share$28.00
Tangible Book Value Per Share$42.14
Margins
Gross margin is 92.61%, with operating margin of 41.45%, and net profit margin of 52.64%.
Gross Margin92.61%
Operating Margin41.45%
Pretax Margin48.69%
Net Profit Margin52.64%
EBITDA Margin43.13%
EBIT Margin41.45%
Analyst Forecast
The average price target for Krystal Biotech is $324.30, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$324.30
Price Target Upside25.38% Upside
Analyst ConsensusStrong Buy
Analyst Count11
Revenue Growth Forecast54.51%
EPS Growth Forecast275.94%